Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-107332
Filing Date
2025-08-12
Accepted
2025-08-12 16:16:01
Documents
69
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q stok-20250630.htm   iXBRL 10-Q 2583904
2 EX-10.1 stok-ex10_1.htm EX-10.1 104720
3 EX-10.2 stok-ex10_2.htm EX-10.2 48113
4 EX-10.3 stok-ex10_3.htm EX-10.3 47072
5 EX-31.1 stok-ex31_1.htm EX-31.1 17852
6 EX-31.2 stok-ex31_2.htm EX-31.2 17657
7 EX-32.1 stok-ex32_1.htm EX-32.1 9505
8 EX-32.2 stok-ex32_2.htm EX-32.2 10558
9 GRAPHIC img146265908_0.jpg GRAPHIC 107205
10 GRAPHIC img146265908_1.jpg GRAPHIC 59555
  Complete submission text file 0000950170-25-107332.txt   9486066

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT stok-20250630.xsd EX-101.SCH 903135
71 EXTRACTED XBRL INSTANCE DOCUMENT stok-20250630_htm.xml XML 1650049
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

EIN.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38938 | Film No.: 251206912
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)